Objective: Numerous studies recently suggested that the immune microenvironment could influence the development of colorectal cancer (CRC). These findings implied that the infiltration of immune cells could be a promising prognostic biomarker for CRC.Methods: Furthermore, the Oncomine database and R2 platform analysis were applied in our research to validate CRC clinical prognosis via expression levels of polyoma enhancer activator 3 (PEA3) members. We explored the correlation of ETV1, ETV4, and ETV5 with tumor-infiltrating immune cells (TIICs) in CRC tumor microenvironments via the Tumor Immune Estimation Resource (TIMER) and Gene Expression Profiling Interactive Analysis (GEPIA). Immunohistochemistry (IHC) was used to validate our CRC clinical data.Results: Our findings indicated that the upregulation of PEA3 members including ETV1 and ETV5 was positively associated with poor prognosis in CRC patients. Meanwhile, ETV1 and ETV5 may play significant roles in the development progress of CRC. Furthermore, ETV1 tends to be associated with immune infiltration of CRC, especially with cancer-associated fibroblasts and M2 macrophages.Conclusion: These findings revealed that ETV1 and ETV5 played significant roles in the development of CRC. Moreover, ETV1 was significantly associated with the infiltration of cancer-associated fibroblasts and M2 macrophages in CRC. Targeting ETV1 can be a potential auspicious approach for CRC treatment.
Colorectal cancer (CRC) is one of the deadliest malignancies worldwide characterized by rapid progression, high metastasis propensity. Our study aimed to identify the driving biological factors of metastatic CRC. We obtained frozen tumor tissues of 8 metastatic CRC (mCRC) patients and 10 non-metastatic CRC (nmCRC) patients from Ruijin Hospital for proteome analysis. FFPE tumor and adjacent normal tissues of another 8 metastatic CRC patients and 8 non-metastatic CRC patients were collected for transcriptome and whole exome sequencing. Mutational burden and signatures were revealed and differentially expressed genes and proteins were analyzed. Molecular Complex Detection was used to build the core network. KEGG and GO pathway enrichment analysis were performed. IHC staining against p-RPS6 and subsequent quantification were performed on human samples. We identified 53,917 SNPs by WES with a median of 1154 variants per sample and 23.08 mutations per megabase (Mb). We observed the mutation burdens were similar between mCRC tumor and nmCRC tumor tissues (p = 0.57), as well as the mutation frequencies of HRR and MMR related genes. All mCRC samples were affected by RTK-RAS, NOTCH and WNT pathway mutations. We constructed a 16-hub-gene network in mCRC which was characterized by dis-modulation of cell adhesion (SELE, SELL and SELP) and immune exhaustion (CXCR2, CCR7, CXCR1, CXCL13, CCL7, CCL19, CXCL11 and CD19) in mCRC tumor microenvironment. We detected 22 differentially expressed proteins, 54 phosphorylated proteins and 6 tyrosine-phosphorylated proteins between mCRC and nmCRC tumors. Phosphorylated RPS6 (p-RPS6) was the most differentially expressed protein between mCRC and nmCRC tumor tissues, which was found to be positively correlated with EMT proteins and poor prognosis in CRC. The IHC staining against p-RPS6 on human samples supported the strong expression in mCRC tumor samples. We identified the key transcriptome network in mCRC and confirmed the important role for RPS6 phosphorylation in mCRC. Our study suggested that the features of mCRC tumors were not driven by gene mutations. We revealed the EMT feature and immune exhaustion of the mCRC tumor microenvironment.